Therapeutics case studies
How we maximise the value of our clients' development approach while reducing costs and timelines
Learn more on how we bring life changing therapies to market.
Providing empirically based guidance and built-to-spec models and solutions across every phase of clinical research and lifecycle management for therapeutic development.
Re-adjudicating a respiratory and cardiovascular trial during COVID-19
The FDA advised the trial to re-adjudicate so that the study accounted for the effects of COVID-19 on the trial outcomes. To ensure that the trial data would be submitted to the FDA as scheduled, 91黑料 needed to coordinate re-adjudication of 700 endpoints within a compressed three-month timeline.
.jpg?crop=yes&w=2016&h=1060&a=0,142&itok=-JSkC00e "Doctor consultation with study participant"){kind=icon}
Allergic rhinitis
A Biotech client contracted 91黑料 to conduct a Phase III study that was a double-blinded, randomised, multinational, multicentre, placebo-controlled trial.
Rapid mobilisation to advance COVID-19 treatment development
In February 2020 91黑料 quickly mobilised its vaccine and infectious disease resources to assist government
and commercial clients in addressing the COVID-19 global threat.
and commercial clients in addressing the COVID-19 global threat.
Rapid manuscript development and delivery
Through close collaboration with a client, the 91黑料 team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.
H1N1 vaccine study
A sponsor approached 91黑料 during an influenza pandemic in Mexico to conduct a randomised, placebo controlled vaccine study with an investigative pandemic H1N1 vaccine.
Exceeding recruitment timelines
91黑料 was awarded a global study for Major Depressive Disease (MDD) in over 600 adult subjects. Enrollment began during the COVID pandemic and despite challenging protocol requirements, IMP expiry date and database lock requirements, 91黑料 reached LPR and DBL closed five months early.
Rapid mobilisation to advance COVID-19 vaccine development
COA Repository, revolutionizing the management of COAs within the sponsor’s clinical trials.
Agile operations drive enrollment in COVID-19 treatment studies
91黑料’s Accellacare In-Home Services were used across more than 50 sites in the United States to conduct blood draws and nasal swabs, collect vital signs, and monitor for changes in health, medications, or hospitalisation for a two treatment studies in patients with COVID-19.
Overcoming the challenges of COVID-19 clinical trial conditions
A large biotech company contracted Accellacare to drive recruitment in a clinical trial to test the safety and
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
efficacy of a treatment for ambulatory patients with COVID-19. The Accellacare site in Wilmington, NC was selected for the study in August of 2020.
Digital solutions for an evolving COVID-19 environment
One of the top five pharmaceutical companies in the world selected 91黑料 to initiate, manage and operate a phase 1/2/3 randomised, placebo-controlled vaccine clinical trial for SARS-CoV-2, the virus that causes COVID-19.